{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T08:41:28Z","timestamp":1788252088634,"version":"build-2803163510"},"reference-count":28,"publisher":"Society of Nuclear Medicine","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Nucl Med"],"accepted":{"date-parts":[[2025,4,29]]},"DOI":"10.2967\/jnumed.125.269746","type":"journal-article","created":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:15Z","timestamp":1747940415000},"page":"jnumed.125.269746","source":"Crossref","is-referenced-by-count":1,"title":["Retreatment of Metastatic Castration-Resistant Prostate Cancer Patients with<sup>223<\/sup>Ra Therapy in Daily Practice"],"prefix":"10.2967","author":[{"given":"Joost H.H.M.","family":"van Riel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten L.","family":"Donswijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christel","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winald R.","family":"Gerritsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.T. Ha","family":"Tan-Phan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul W.L.","family":"Thimister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Noordzij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik T.","family":"Te Beek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence J.C.","family":"van Warmerdam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andries M.","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk N.J.","family":"Wyndaele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"van der Doelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1602","published-online":{"date-parts":[[2025,5,22]]},"reference":[{"key":"2025052212000811000_jnumed.125.269746v1.1","doi-asserted-by":"publisher","DOI":"10.3322\/CAAC.21834"},{"key":"2025052212000811000_jnumed.125.269746v1.2","unstructured":"Netherlands Cancer Registry. Netherlands Comprehensive Cancer Organisation website. nkr-cijfers.iknl.nl. Accessed August 12, 2024."},{"key":"2025052212000811000_jnumed.125.269746v1.3","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II: 2024 update\u2013\u2014treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur Urol."},{"key":"2025052212000811000_jnumed.125.269746v1.4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0931"},{"key":"2025052212000811000_jnumed.125.269746v1.5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.22991"},{"key":"2025052212000811000_jnumed.125.269746v1.6","first-page":"3120","article-title":"Significant antitumor effect from bone-seeking, alpha-particle-emitting 223Ra demonstrated in an experimental skeletal metastases model","volume":"62","author":"Henriksen","year":"2002","journal-title":"Cancer Res."},{"key":"2025052212000811000_jnumed.125.269746v1.7","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-2955"},{"key":"2025052212000811000_jnumed.125.269746v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213755"},{"key":"2025052212000811000_jnumed.125.269746v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70183-4"},{"key":"2025052212000811000_jnumed.125.269746v1.10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw065"},{"key":"2025052212000811000_jnumed.125.269746v1.11","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1007\/s00259-019-4261-y","article-title":"Interim analysis of the REASSURE (radium-223 alpha emitter agent in non-intervention safety study in MCRPC population for long-term evaluation) study: patient characteristics and safety according to prior use of chemotherapy in routine clinical practice","volume":"46","author":"Dizdarevic","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052212000811000_jnumed.125.269746v1.12","doi-asserted-by":"crossref","first-page":"101993","DOI":"10.1016\/j.eclinm.2023.101993","article-title":"Clinical outcomes and treatment patterns in REASSURE: planned interim analysis of a real-world observational study of radium-223 in metastatic castration-resistant prostate cancer","volume":"60","author":"Higano","year":"2023","journal-title":"EClinicalMedicine."},{"key":"2025052212000811000_jnumed.125.269746v1.13","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1093\/annonc\/mdx331","article-title":"Re-treatment with radium-223: first experience from an international, open-label, phase I\/II study in patients with castration-resistant prostate cancer and bone metastases","volume":"28","author":"Sartor","year":"2017","journal-title":"Ann Oncol."},{"key":"2025052212000811000_jnumed.125.269746v1.14","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1002\/pros.23893","article-title":"Re-treatment with radium-223: 2-year follow-up from an international, open-label, phase 1\/2 study in patients with castration-resistant prostate cancer and bone metastases","volume":"79","author":"Sartor","year":"2019","journal-title":"Prostate."},{"key":"2025052212000811000_jnumed.125.269746v1.15","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s00259-017-3900-4","article-title":"EANM guideline for radionuclide therapy with radium-223 of metastatic castration-resistant prostate cancer","volume":"45","author":"Poeppel","year":"2018","journal-title":"Eur J Nucl Med Mol Imaging."},{"key":"2025052212000811000_jnumed.125.269746v1.16","unstructured":"Common Terminology Criteria for Adverse Events, version5.0. Cancer Therapy Evaluation Program website. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm#ctc_50. Updated November 27, 2017. Accessed May 5, 2025."},{"key":"2025052212000811000_jnumed.125.269746v1.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.2702"},{"key":"2025052212000811000_jnumed.125.269746v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"2025052212000811000_jnumed.125.269746v1.19","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.119.233817"},{"key":"2025052212000811000_jnumed.125.269746v1.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.025"},{"key":"2025052212000811000_jnumed.125.269746v1.21","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.123.266125"},{"key":"2025052212000811000_jnumed.125.269746v1.22","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1002\/ijc.32851","article-title":"A prospective observational registry evaluating clinical outcomes of radium-223 treatment in a nonstudy population","volume":"147","author":"Badrising","year":"2020","journal-title":"Int J Cancer."},{"key":"2025052212000811000_jnumed.125.269746v1.23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.euo.2019.02.007","article-title":"Radium-223 within the evolving treatment options for metastatic castration-resistant prostate cancer: recommendations from a European expert working group","volume":"3","author":"O\u2019Sullivan","year":"2020","journal-title":"Eur Urol Oncol."},{"key":"2025052212000811000_jnumed.125.269746v1.24","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1002\/cncr.35221","article-title":"Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE)","volume":"130","author":"Higano","year":"2024","journal-title":"Cancer."},{"key":"2025052212000811000_jnumed.125.269746v1.25","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.121.262240"},{"key":"2025052212000811000_jnumed.125.269746v1.26","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/cancers14030557","article-title":"Safety and efficacy of 177lutetium-PSMA-617 radioligand therapy shortly after failing 223radium-dichloride","volume":"14","author":"Baumgarten","year":"2022","journal-title":"Cancers (Basel)."},{"key":"2025052212000811000_jnumed.125.269746v1.27","doi-asserted-by":"crossref","first-page":"1059122","DOI":"10.3389\/fmed.2022.1059122","article-title":"AlphaBet: combination of radium-223 and [177Lu]Lu-PSMA-I&T in men with metastatic castration-resistant prostate cancer (clinical trial protocol)","volume":"9","author":"Kostos","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"2025052212000811000_jnumed.125.269746v1.28","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","article-title":"A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC)\u2014first results of EORTC-GUCG 1333\/PEACE-3 [abstract]","volume":"35(suppl 2)","author":"Gillessen","year":"2024","journal-title":"Ann Oncol."}],"container-title":["Journal of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.2967\/jnumed.125.269746","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,22]],"date-time":"2025-05-22T19:00:19Z","timestamp":1747940419000},"score":1,"resource":{"primary":{"URL":"http:\/\/jnm.snmjournals.org\/lookup\/doi\/10.2967\/jnumed.125.269746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,22]]},"references-count":28,"alternative-id":["10.2967\/jnumed.125.269746"],"URL":"https:\/\/doi.org\/10.2967\/jnumed.125.269746","relation":{},"ISSN":["0161-5505","2159-662X"],"issn-type":[{"value":"0161-5505","type":"print"},{"value":"2159-662X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,22]]}}}